Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) announced that Enhertu (trastuzumab deruxtecan)...

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced that Imfinzi (durvalumab) has been officially approved in China for use...

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Fineline Cube Jan 22, 2026

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) announced that China’s National Medical Products Administration...

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Fineline Cube Jan 22, 2026

Abbott (NYSE: ABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo...

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has...

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Fineline Cube Jan 22, 2026

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37, a next‑generation once‑monthly subcutaneous GLP‑1R/GIPR/GCGR triple‑agonist...

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026

Novavax, Inc. (NASDAQ: NVAX) entered into a license agreement with Pfizer Inc. for non‑exclusive rights to...

Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Fineline Cube Jan 22, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that China’s National Medical Products Administration (NMPA) has...

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026

Zhejiang-based BioRay Pharmaceutical Co., Ltd announced an initial public offering (IPO) filing to the Hong...

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026

Bristol‑Myers Squibb (BMS, NYSE: BMY) announced a collaboration with Microsoft to accelerate early detection of non‑small...

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026

Bayer AG (ETR: BAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five‑year collaboration to...

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026

Hangzhou Diagens Biotechnology Co., Ltd. announced a filing for an initial public offering (IPO) to...

Others

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Fineline Cube Jan 22, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026

Alteogen Inc. (KOSDAQ: 196170) announced an exclusive license agreement with Tesaro, a GSK subsidiary, granting worldwide...

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Fineline Cube Jan 22, 2026

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Fineline Cube Jan 22, 2026

Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon‑2...

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026

Eyebright Medical Technology Co., Ltd (SHA: 688050) announced plans to acquire a controlling stake of...

Company

AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification

Fineline Cube Jan 22, 2026

AstraZeneca plc (AZ, NASDAQ: AZN) announced it will delist its American Depositary Shares (ADS) and debt...

Posts pagination

1 … 107 108 109 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.